Epilepszia: vizsgálatok itt: Portugália
6 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleInvestigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- Where
- Almada, Lisbon, Porto
- Életkor
- 4 év to 55 év
- People
- 252 worldwide
- Run by
- SK Life Science, Inc.
See details and how to joinNCT05219617 - 3. fázisTaking peopleA Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
- Where
- Coimbra, Guimarães, Lisbon, Santa Maria Da Feira, Senhora Da Hora
- Életkor
- 12 év and over
- People
- 160 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05667142 · EU 2022-502286-16-00 - 3. fázisTaking peopleA Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
- Where
- Coimbra, Guimarães, Lisbon, Porto, Santa Maria Da Feira, Senhora Da Hora, Vila Real
- Életkor
- 18 év and over
- People
- 360 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05716100 · EU 2022-502281-25-00 - 3. fázisCsak meghívásosAn Open-label Study of XEN1101 in Epilepsy
- Where
- Coimbra, Guimarães, Lisbon, Porto, Santa Maria Da Feira, Senhora Da Hora, Vila Real
- Életkor
- 12 év and over
- People
- 880 worldwide
- Run by
- Xenon Pharmaceuticals Inc.
See details and how to joinNCT05718817 · EU 2022-502282-24-00 - 3. fázisCsak meghívásosA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
- Where
- Coimbra, Lisbon, Porto
- Életkor
- 2 év to 66 év
- People
- 324 worldwide
- Run by
- Longboard Pharmaceuticals
See details and how to joinNCT06908226 · EU 2024-514974-39-00 - 2. fázisCsak meghívásosLong-term Safety and Tolerability of BHV-7000
- Where
- Braga, Coimbra, Lisbon, Matosinhos, Santa Maria Da Feira
- Életkor
- 18 év to 75 év
- People
- 660 worldwide
- Run by
- Biohaven Therapeutics Ltd.
See details and how to joinNCT06443463 · EU 2023-508813-18-00